What changed for Irritable Bowel Syndrome
A plain English summary of what recently moved in the public data Voxsanity tracks for Irritable Bowel Syndrome. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 105 to 106 (+1)
- Trials on record 1,021 to 1,026 (+5)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Irritable Bowel Syndrome yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Irritable Bowel Syndrome that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05744258 · results posted 29 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 people in total — 20 people who had been diagnosed with Irritable Bowel Syndrome (IBS) and 20 healthy volunteers without IBS. Of the IBS group, 16 people completed the study (4 did not finish), while all 20 healthy volunteers completed it. The trial was not testing a treatment; instead, it was measuring differences in body composition — things like body water, muscle, and fat levels — between the two groups. These measurements were taken using a technique called Bio-electrical Impedance Analysis (BIA), which sends...
-
NCT03983434 · results posted 30 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03983434) enrolled 29 people in total across three groups: 17 healthy volunteers, 3 people with irritable bowel syndrome (IBS) with constipation, and 9 people with IBS with diarrhoea. The trial measured certain chemicals found in stool — specifically bile acids (substances involved in digestion) and short-chain fatty acids (substances produced by gut bacteria when they break down food) — as well as the variety of bacteria living in the gut. Stool samples were collected over 48 hours and analysed in a laboratory. Not everyo...
-
NCT02291445 · results posted 24 January 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 8 people in total — 4 in each group — and all 8 completed the study. It was a crossover trial, meaning each participant tried both forms of peppermint oil capsule at different times: one that releases in the small intestine, and one that releases further along in the gut (in the ileocolonic region, which is where the small and large intestines meet). The trial was measuring how a substance called menthol-glucuronide — the main form peppermint oil takes after being processed by the liver — behaved in the bloodstream af...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01199302 · results posted 28 December 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 67 people in total across four groups. Each group received a different dosing arrangement of brodalumab (an investigational medicine) or a placebo, with most participants later switching to a standard dose of brodalumab. The trial was measuring undesirable medical events that occurred during treatment, changes in disease activity scores for Crohn's disease (a condition causing ongoing gut inflammation), and whether participants' scores crossed thresholds defined as a meaningful response or remission. The reported dat...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03806127 · results posted 30 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03806127) enrolled 222 adults with a type of irritable bowel syndrome characterised by diarrhoea (IBS-D), with 111 people assigned to receive a daily 75 mg dose of a medicine called vibegron and 111 people assigned to receive a placebo (a dummy pill with no active ingredient). By the end of the 12-week study, 99 people in the vibegron group and 90 in the placebo group had completed the trial. The main thing the trial was measuring was how many participants in each group experienced a meaningful reduction in their worst abd...
-
NCT01412372 · results posted 31 December 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 61 people in total — 30 in the placebo group and 31 in the mesalamine group. Of those, 26 and 28 participants respectively finished the full study. The trial ran for eight weeks and was measuring whether mesalamine (a medication sometimes used for gut inflammation) had any impact on bowel symptoms, quality of life, and related measures in people with irritable bowel syndrome (IBS), compared to a placebo (a dummy treatment with no active ingredient). The reported data shows that the main thing being measured was a "Bo...
-
NCT03241368 · results posted 9 June 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 158 people who already had a known diagnosis of Crohn's disease. The trial was comparing three different ways of looking at the bowel for signs of active Crohn's disease: capsule endoscopy (CE, where a person swallows a tiny camera in a pill), ileocolonoscopy (IC, a standard camera procedure), and MR enterography (MRE, a type of MRI scan that looks at the bowel). Of the 158 people who started, 119 completed the trial and 39 did not complete it. The reported data shows that the primary thing being measured was how acc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02559206 · results posted 24 April 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 532 adults across eight groups to compare different formulations and doses of a drug called linaclotide against a placebo (a dummy treatment) in people with a condition involving abdominal pain and constipation. The drug was tested in its standard form (IR, meaning immediate-release) as well as two newer delayed-release versions (DR1 and DR2) at three different doses each — 30, 100, and 300 micrograms. The trial ran for 12 weeks and measured two main things: how much abdominal pain changed over time (rated on a 0–10 s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02544152 · results posted 27 December 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 71 people in total — 34 in the placebo group and 37 in the lubiprostone group. The trial was measuring how well participants with abdominal pain responded to treatment over a number of weeks, using a scale where participants rated their worst pain in the past 24 hours from 0 (no pain) to 10 (worst possible pain). The main thing the trial was looking at was how many people in each group could be classed as an "overall responder" for abdominal pain — meaning their pain had dropped by at least 30% compared to their start...
-
NCT03154086 · results posted 9 August 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT03154086) tested an investigational medicine called GSK3352589. It was run in two main parts. Part A was an early-stage, dose-finding section where healthy volunteers received single doses of GSK3352589 (ranging from 2 mg up to 400 mg) or a placebo (a dummy treatment with no active ingredient), with some sessions testing the drug on an empty stomach versus after a meal. Part B then looked at participants receiving twice-daily doses (ranging from 5 mg to 200 mg) or placebo over a longer period. Across all the groups and dos...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00765999 · results posted 15 February 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT00765999) enrolled 1,554 participants, all of whom received the study drug linaclotide. This was a single-group, open-label study, meaning everyone received the same treatment with no comparison group. Of those who started, 770 completed the study and 784 did not complete it. The trial was measuring what happened to participants while they were taking linaclotide, with a focus on tracking any unwanted or unexpected medical events (called "treatment-emergent adverse events," or TEAEs) that occurred after starting the medica...
-
NCT02641392 · results posted 29 January 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02641392) involved three groups of participants who received different doses or schedules of a drug called GED-0301: 4 people received a 40 mg alternating schedule, 13 received a standard 40 mg dose, and 293 received a 160 mg alternating schedule — giving a total of 310 participants. The trial ran for up to 208 weeks (roughly four years). Notably, the reported data shows that none of the participants in any group were recorded as having completed the study — all participants were listed under "not completed." The primary...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02757105 · results posted 31 July 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 75 people in the RHB-102 group and 52 people in the placebo (dummy pill) group — 127 participants in total. The trial was measuring what is called a "stool consistency response" in people with diarrhoea-predominant irritable bowel syndrome (IBS-D). To count as a "responder," a participant needed to have at least 50% fewer days per week with loose or watery stools (rated Type 6 or 7 on a standard stool chart), without any notable increase in their abdominal pain, and they needed to meet this target in at least half of...
-
NCT02388269 · results posted 6 February 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02388269) looked at a device called gammaCore®-G in people with functional gastrointestinal disorders — specifically functional dyspepsia (a condition causing ongoing stomach discomfort or pain without a clear physical cause) and irritable bowel syndrome (IBS). A total of 91 people were enrolled: 41 were randomly assigned to the active device, 40 to a sham (dummy) version of the device, and 10 were in a non-randomised group. Of those randomly assigned, 32 in the active group and 38 in the sham group completed the study. Th...
-
NCT00421707 · results posted 26 December 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 132 participants in total — 67 in one sequence group and 65 in the other. It was a crossover study, meaning participants received different treatments at different times, separated by a washout (rest) period. The trial was testing a medicine called GW876008 (at a dose of 125 mg) against a placebo (a dummy treatment with no active ingredient) in people with Irritable Bowel Syndrome (IBS). The study aimed to measure things like relief from IBS pain and discomfort, overall symptom improvement, and quality of life. The r...
-
NCT00477165 · results posted 17 April 2017
According to the results reported on ClinicalTrials.gov, this trial looked at whether citalopram (an antidepressant sometimes explored for gut symptoms, spelled "Cialopram" in the participant data but referred to as "Citalopram" in the outcome measures) compared to a placebo (a dummy treatment) could provide relief for people with Irritable Bowel Syndrome (IBS). A total of 54 people took part — 27 in each group. Of those, 20 people in the citalopram group and 25 in the placebo group completed the study, meaning 7 people in the citalopram group and 2 in the placebo group did not finish. The re...
-
NCT02120027 · results posted 18 January 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT02120027) enrolled 277 women in the ibodutant 10 mg group and 279 women in the placebo (dummy tablet) group — 556 participants in total. The trial was measuring whether ibodutant reduced two key symptoms of irritable bowel syndrome with diarrhoea (IBS-D): abdominal pain and loose/watery stools. To count as a "responder," a participant needed to show meaningful improvement in both symptoms during at least half of the 24-week treatment period (that is, at least 12 out of 24 weeks). The reported data shows that for the main...
-
NCT02107196 · results posted 27 September 2016
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called ibodutant (10 mg) compared to a placebo (a dummy pill with no active ingredient) in women with irritable bowel syndrome with diarrhoea (IBS-D). The trial had two stages: a 12-week treatment period, in which 271 people started on ibodutant and 264 on placebo, followed by a 4-week withdrawal period involving a separate group of 338 and 114 participants respectively. The trial was primarily measuring how many participants had meaningful improvements in both abdominal pain and stool consistency at the s...
-
NCT01880424 · results posted 27 September 2016
According to the results reported on ClinicalTrials.gov, this trial enrolled 839 people — 417 in the linaclotide group and 422 in the placebo group (a placebo is a dummy treatment with no active ingredient, used for comparison). The trial was measuring symptoms of Irritable Bowel Syndrome with Constipation (IBS-C), specifically looking at abdominal pain and discomfort, overall IBS symptom relief, and bowel movement patterns over 12 weeks. By the end of the study, 384 people in the linaclotide group and 367 in the placebo group had completed the trial. The reported data shows the following num...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00724126 · results posted 28 July 2014
According to the results reported on ClinicalTrials.gov, this trial enrolled 637 adults — 321 in the placebo group (a dummy treatment with no active ingredient) and 316 in the rifaximin group. The trial was measuring whether rifaximin, an antibiotic, made a difference to self-reported irritable bowel syndrome (IBS) symptoms. Participants were asked each week whether they felt adequate relief from their overall IBS symptoms, and separately, whether they felt adequate relief from bloating. The main results window covered weeks 3 to 6 of the study, which was the four-week period immediately after...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00731679 · results posted 28 July 2014
According to the results reported on ClinicalTrials.gov, this trial enrolled 623 adults — 314 in the placebo group (a dummy treatment with no active ingredient) and 309 in the rifaximin group. The trial was measuring whether people with irritable bowel syndrome (IBS) felt adequate relief from their overall IBS symptoms, and separately from bloating, during the four weeks after finishing two weeks of treatment. Each week, participants were simply asked "yes or no" whether they had felt adequate relief compared to how they felt before the study started. The reported data shows that for overall...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01331213 · results posted 3 March 2014
According to the results reported on ClinicalTrials.gov, this trial (NCT01331213) enrolled 18 people in total — 8 received pregabalin (a medicine sometimes used for nerve-related conditions) and 10 received a placebo (a dummy treatment with no active ingredient). All 18 participants completed the study with no drop-outs. The trial was measuring how pregabalin compared to placebo on several aspects of how the large bowel (colon) works, including how stiff or flexible the colon is, how it responds to eating a meal, and at what point participants first felt pain when the colon was gently inflated...
-
NCT01327300 · results posted 12 February 2014
According to the results reported on ClinicalTrials.gov, this was a small crossover trial — meaning the same participants took both the active treatment (mesalamine) and a placebo at different times, with a three-week "washout" break in between. Seven people were enrolled in total: five started in the group that received mesalamine first, and two started with placebo first. One person dropped out during the washout period, so six people completed the full trial. The trial was measuring changes in gut (gastrointestinal) symptoms, bowel disease severity, quality of life, anxiety and depression s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01303224 · results posted 25 March 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 565 people in total across four groups. Participants were randomly assigned to take one of three doses of a medicine called ibodutant (1 mg, 3 mg, or 10 mg) or a placebo (a dummy pill with no active ingredient) once daily for 8 weeks. The trial was measuring how many people with irritable bowel syndrome (IBS) reported satisfactory relief of their overall IBS symptoms **and** their abdominal pain or discomfort for at least 6 out of 8 weeks of treatment. The reported data shows that, for the main outcome (satisfactory...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00948818 · results posted 30 January 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 397 people in the placebo group and 406 people in the linaclotide group — 803 participants in total. The trial was measuring whether linaclotide, compared to a dummy pill (placebo), made a difference to two key symptoms of irritable bowel syndrome with constipation (IBS-C): abdominal (tummy) pain, and the number of "complete spontaneous bowel movements" (CSBMs) — that is, bowel movements that happened without laxatives and left the person feeling fully emptied. By the end of the 12-week treatment period, 335 placebo p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00761007 · results posted 1 October 2010
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called ibodutant, tested at three different doses (10 mg, 30 mg, and 60 mg), compared against a placebo (a dummy treatment with no active ingredient) in people with irritable bowel syndrome (IBS). A total of 554 people were enrolled across the four groups, and the trial was measuring whether participants reported satisfactory relief of their overall IBS symptoms over a four-week period. The reported data shows that for the main (primary) outcome — defined as saying "yes" to feeling satisfactory symptom...
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public research investment in Irritable Bowel Syndrome sits at a moderate level, which suggests the condition has attracted meaningful attention from government researchers. However, the direction of that funding has been falling year on year, meaning the research effort supported by public dollars appears to be easing back rather than growing. For patients, this pat...
See the full Irritable Bowel Syndrome page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.